FY2023 Q1 Financial Results Presentation

from the beginning

FY2023 Q1 Financial Results Presentation

Forward-Looking Statements

1. FY2023 Q1 Financial Results

Overview of FY2023 Q1 Results

Revenue

Core Operating Profit

Profit Attributable to Owners of the Company

Revenue: Business Units (incl. Forex Impact)

Revenue: Major Products in Japan

2. Business Update

Revenue

Performance in Each Region (US, EU)

Performance in Each Region (Japan, ASCA)

Initiatives Related to Profit Growth for Current Business and Products in Japan

3. R&D Update

5DXd-ADCs Update

From “3 and Alpha”to“5DXd-ADCs and Next Wave”

Promising antitumor activity in HER2+ mCRC patients DESTINY-CRC02 study (ASCO 2023)

Potential new treatment option for HER2 expressing solid tumors DESTINY-PanTumor02 study (ASCO 2023)

Primary analysis of DESTINY-PanTumor02 study

Encouraging Combination Data in 1L NSCLC TROPION-Lung02 study（ASCO 2023）

Path for establishing 2L/3L treatment in NSCLC

TROPION-Lung01 study

Additional updates in clinical studies and regulatory communications

Next Wave Update

New project: DS-3939 starts Ph1/2 study

New project: DS-1471 starts Ph1 study

Clinical and Regulatory Progress

News Flow

FY2023 News Flow

Appendix

Major R&D Milestones (5DXd-ADCs (1))

Major R&D Milestones (5DXd-ADCs (2))

Major R&D Milestones (Next Wave)

Major R&D Pipeline: 5DXd-ADCs

Major R&D Pipeline: Next Wave

Contact address regarding this material

Q&A

• Q&A 1

• Q&A 2

• Q&A 3

• Q&A 4

• Q&A 5

• Q&A 6

• Q&A 7